ClinicalTrials.gov
ClinicalTrials.gov Menu

Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00283803
Recruitment Status : Completed
First Posted : January 30, 2006
Results First Posted : May 14, 2018
Last Update Posted : May 14, 2018
Sponsor:
Collaborator:
OSI Pharmaceuticals
Information provided by (Responsible Party):
Celestia Higano, University of Washington

January 26, 2006
January 30, 2006
October 17, 2017
May 14, 2018
May 14, 2018
March 12, 2002
October 2011   (Final data collection date for primary outcome measure)
  • Duration of the First "Off-treatment" Cycle in Patients Who Have Completed One Cycle of Intermittent Androgen Suppression With the Addition of Exisulind. [ Time Frame: From date of first treatment until the date of first documented progression or study withdrawal, whichever came first, assessed up to 10 years. ]
    Patients were monitored for the amount of time (number of weeks) that passed between the completion of a cycle of Intermittent Androgen Suppression with Exisulind and the need to re-initiate treatment with Intermittent Androgen Suppression. It was hoped that adding Exisulind to standard Androgen Suppression would extend the amount time before disease progression.
  • Time to Hormone-refractory Diseases in Patients Treated With Intermittent Androgen Suppression and Exisulind [ Time Frame: From date of first treatment until the date of first documented progression or study withdrawal, whichever came first, assessed up to 10 years. ]
    Patients were monitored for continued hormonal sensitivity of their disease from the time of the first treatment with Intermittent Androgen Suppression and Exisulind and the time at which point they were considered hormone-refractory (castrate resistant). The development of hormone-refractory disease was one of the criteria for withdraw from study treatment. For this protocol, hormone-refractory was defined as 2 consecutive rising PSAs at least 2 weeks apart while on an LHRH agonist (with or without an anti-androgen).
  • Number of Participants With Dose Hold, Dose Reduction, or Treatment Withdrawal for Toxicity. [ Time Frame: From date of first treatment until study withdrawal, assessed up to 10 years. ]
    Patients were monitored for toxicity related treatment modifications from the start of Exisulind through the time that there were withdrawn from study.
To determine whether the addition of exisulind to the treatment of patients who have completed at least ONE cycle of IAS will extend the "off-treatment" cycle.
Complete list of historical versions of study NCT00283803 on ClinicalTrials.gov Archive Site
Not Provided
To determine the time to hormone-refractory diseases in the patients who are taking exisulind with IAS
Not Provided
Not Provided
 
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
Evaluation of the Effect of Exisulind on the Duration of the "Off-Treatment" Interval on Patients With Biochemical Relapse of Prostate Cancer Who Are Treated With Intermittent Androgen Suppression (ADT)

The purpose of this research study is to determine if an investigational drug called Exisulind will extend the "off-treatment" period of patients receiving Intermittent Androgen Suppression (ADT).

There is evidence suggesting that alternating between periods of treatment and no treatment with androgen suppressants may delay the time to develop androgen-insensitive progression and improve overall quality of life. During intermittent androgen suppression (IAS) treatments, men receive a luteinizing hormone-releasing hormone (LHRH) agonist and antiandrogen for a fixed period of time (approximately 9 months) and then enter an off-treatment period, whose length will vary, depending on the rate of rise in the patient's Prostate-Specific Antigen (PSA). Once the PSA reaches an established threshold (1 ng/mL in men who have had a prostatectomy or 4 ng/ml in men with an intact prostate), androgen suppression will be re-initiated for another 9 months. These cycles of on-treatment/off-treatment will be repeated until patient no longer responds to the androgen suppression and it is clear that their cancer is progressing. It has been observed that off-treatment periods tend to become shorter with each successive cycle of androgen suppression, presumably due to the emergence of androgen-independent clones. This study proposes to look at exisulind, a pro-apoptotic drug, which may extend the off-treatment period in patients receiving IAS.

A study doctor will meet with you and ask you about your medical history, examine you, and explain the study. We will draw some blood for tests (about 4-6 tablespoons), including Prostate-Specific Antigen (PSA). If not already obtained, you will have a bone scan and a computed tomography scan (CT scan) to establish a baseline.

You will be receiving hormone suppression treatment with monthly injections of a luteinizing hormone-releasing hormone (LHRH) analog such as Lupron or Zoladex and an antiandrogen such as Eulexin or Casodex as part of your standard care for prostate cancer. About 3 months before your next "off-treatment" period, you will start 1 Exisulind pill 250 mg (2 x 125mg capsules) by mouth twice a day. It is necessary for you to start the Exisulind treatment 3 months prior to your next "off-treatment" period so that the medication can build up in your system enough to be effective.

Per our standard follow-up procedures, we will ask you to have blood draws every 2 weeks for up to 12 weeks after starting Exisulind to check liver function. Thereafter you will be asked to have monthly blood draws, and return to the clinic every 3 months for a physical examination, to determine how well you are tolerating the study medication, how your cancer is responding to the treatment, and to give you more study medication. You will continue taking Exisulind during your "off-treatment" period until your PSA reaches a threshold level. PSA threshold is defined by your primary treatment. If you have had your prostate removed, the threshold is 1.0 ng/dL. If you have an intact prostate, your threshold is 4 ng/dL. Once your PSA reaches this level, you will restart your hormone suppression treatment as directed by your doctor.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Prostate Cancer
  • Drug: Exisulind
    Oral antineoplastic agent that induces apoptosis in cancerous cells.
    Other Name: Aptosyn
  • Drug: luteinizing hormone-releasing hormone (LHRH) agonist
    Hormonal therapy to suppress testosterone as a standard treatment for Prostate Cancer.
    Other Names:
    • Lupron
    • Zoladex
  • Drug: Antiandrogen
    Hormonal therapy used as lead in treatment with luteinizing hormone-releasing hormone (LHRH) agonist to prevent the initial rise in testosterone (testosterone flare) seen during the first dose of LHRH agonists.
    Other Names:
    • Eulexin
    • Casodex
Experimental: IAS and Exisulind
Patients will receive intermittent dosing of hormone therapy with commercially supplied luteinizing hormone-releasing hormone (LHRH) agonist and anti-androgen to be chosen by physician per standard of care. Exisulind will be started 3 months prior to the end of the second cycle of hormone therapy. Patients will continue treatment with Exisulind beyond the completion of the second cycle of hormone therapy until they meet criteria for discontinuation.
Interventions:
  • Drug: Exisulind
  • Drug: luteinizing hormone-releasing hormone (LHRH) agonist
  • Drug: Antiandrogen
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
32
Same as current
October 2011
October 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • A willingness and ability to sign an informed consent document;

    • 21 years or of legal age;
  • Histologically or cytologically documented prostate cancer.
  • ECOG Performance status score of 0 or 1.
  • Received at least one cycle of IAS with an LHRH agonist and anti-androgen
  • Willingness to remain off chronic NSAIDs (with the exception of ibuprofen or naproxen), including COX 2 inhibitors and salicylates (e.g., aspirin, mesalamine, azodisalicylate, salsalate, sulfasalazine) for duration of the study. Patients on low dose aspirin for cardiovascular prevention may be included in the study.
  • Have not taken sulindac (Clinoril™) on regular basis for any indication for one week prior to enrollment and willing to remain off of sulindac for the duration of the study.
  • Patients with prior radiation must be 2 weeks from their last radiation-treatment and have recovered from all associated toxicity.

Exclusion Criteria:

  • Known hypersensitivity to sulindac (Clinoril™)
  • ECOG Performance status score > 1;
  • Patients previously on SWOG 9346 or 9921 trials, or any other trials using IAS for which adding exisulind may be confounding.
  • Patients may not have any evidence of hormone-refractory prostate cancer, i.e. 2 consecutive rises in PSA on LHRH agonist and anti-androgen
  • Active peptic ulcer disease;
  • Use of an investigational medication or device within one month of initiating study therapy;
  • Elevations of serum creatinine to above the upper limit of normal;
  • Platelet count < 100,000/L; hgb < 9.0 g/dL; absolute neutrophil count < 1500/mm3
  • Known hepatic, biliary tract, renal or hematologic dysfunction which in the opinion of the Investigator or Sponsor are clinically significant or would obscure laboratory analyses or are associated with lab abnormalities;
  • Any condition or any medication that may interfere with the conduct of the study.
  • Bilirubin > ULN. Patients with elevated indirect bilirubin due to Gilbert's Syndrome will be eligible.
  • AST or ALT >2.5 X ULN
Sexes Eligible for Study: Male
21 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00283803
44830
EX1006 ( Other Identifier: OSI Pharmaceuticals )
No
Not Provided
Plan to Share IPD: No
Celestia Higano, University of Washington
University of Washington
OSI Pharmaceuticals
Principal Investigator: Celestia Higano, MD University of Washington
University of Washington
April 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP